BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31229873)

  • 1. 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development.
    Zhuo LS; Xu HC; Wang MS; Zhao XE; Ming ZH; Zhu XL; Huang W; Yang GF
    Eur J Med Chem; 2019 Sep; 178():705-714. PubMed ID: 31229873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate.
    Chen T; Zhuo LS; Liu PF; Fang WR; Li YM; Huang W
    Eur J Med Chem; 2020 Apr; 192():112174. PubMed ID: 32113049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold.
    Wang MS; Zhuo LS; Yang FP; Wang WJ; Huang W; Yang GF
    Eur J Med Chem; 2020 Jan; 185():111803. PubMed ID: 31677447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy.
    Zhuo LS; Wu FX; Wang MS; Xu HC; Yang FP; Tian YG; Zhao XE; Ming ZH; Zhu XL; Hao GF; Huang W
    Eur J Med Chem; 2020 Dec; 208():112785. PubMed ID: 32898795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
    Liu Y; Jin S; Peng X; Lu D; Zeng L; Sun Y; Ai J; Geng M; Hu Y
    Eur J Med Chem; 2016 Jan; 108():322-333. PubMed ID: 26698536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.
    Nan X; Zhang J; Li HJ; Wu R; Fang SB; Zhang ZZ; Wu YC
    Eur J Med Chem; 2020 Aug; 200():112470. PubMed ID: 32505087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
    Nan X; Li HJ; Fang SB; Li QY; Wu YC
    Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
    Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
    Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
    [No Abstract]   [Full Text] [Related]  

  • 13. Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors.
    She N; Zhuo L; Jiang W; Zhu X; Wang J; Ming Z; Zhao X; Cong X; Huang W
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3351-5. PubMed ID: 24951334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
    Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
    Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors.
    Zhang QW; Ye ZD; Shen C; Tie HX; Wang L; Shi L
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):124-133. PubMed ID: 30422010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors.
    Tang Q; Wang L; Duan Y; Wang W; Huang S; Zhi J; Jia S; Zhu W; Wang P; Luo R; Zheng P
    Eur J Med Chem; 2017 Jun; 133():97-106. PubMed ID: 28384549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking.
    Ahmed EM; Khalil NA; Taher AT; Refaey RH; Nissan YM
    Bioorg Chem; 2019 Nov; 92():103272. PubMed ID: 31539742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
    Tang Q; Zhao Y; Du X; Chong L; Gong P; Guo C
    Eur J Med Chem; 2013 Nov; 69():77-89. PubMed ID: 24012712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2.
    Xu H; Wang M; Wu F; Zhuo L; Huang W; She N
    Bioorg Med Chem; 2020 Jun; 28(12):115555. PubMed ID: 32503697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.
    Liu Z; Wang R; Guo R; Hu J; Li R; Zhao Y; Gong P
    Bioorg Med Chem; 2014 Jul; 22(14):3642-53. PubMed ID: 24882675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.